MAY 06, 2020 / 8:15PM GMT, Q1 2020 Precigen Inc Earnings Call CORPORATE PARTICIPANTS Helen Sabzevari Precigen, Inc. - President & CEO Steven Harasym Precigen, Inc. - Head of Investor Relations Tom Samuelson Precigen, Inc

Call CORPORATE PARTICIPANTS Helen Sabzevari Precigen, Inc. - President & CEO Steven Harasym Precigen, Inc. - Head of Investor Relations Tom Samuelson Precigen, Inc. - Head of Financial Strategy CONFERENCE CALL PARTICIPANTS Jason Nicholas Butler

JMP Securities LLC, Research Division - MD and Senior Research Analyst Swayampakula Ramakanth H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst PRESENTATION Operator Good afternoon, and welcome

to the Precigen First Quarter 2020 Business Update and Financial Results Conference Call. I will now turn the call over to Steve Harasym, Head of Investor Relations. Please go ahead. Steven Harasym Precigen, Inc. - Head of Investor Relations Thank

you, operator. I am pleased to be joined today by Dr. Helen Sabzevari, President and CEO of Precigen; and Tom Samuelson, Head of Financial Strategy. Please turn to Slide 2 for our forward-looking statement. During today's call, we will make various

forward-looking statements. Investors are cautioned that our forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those

indicated by our forward-looking statements. Please read the safe harbor statement contained in this presentation as well as the risk factors contained in Precigen's most recent SEC filings, for a more complete discussion of these risks and

uncertainties. I will now turn the call over to Dr. Sabzevari. Helen Sabzevari Precigen, Inc. - President & CEO Thank you, Steve. I hope that this call finds all our listeners and their families safe and healthy. Since we last spoke in March, so

much has changed. We are living through an historic moment that has caused profound change from all perspectives: scientific, economic, sociologic and psychologic. Our nation and the world are making progress in working together to overcome the

challenge of COVID-19. At Precigen, the health and safety of our employees is of the utmost importance. Our corporate employees have transitioned seamlessly to working remotely, and essential personnel, including research scientists, are in the lab

and practicing all appropriate safety measures, social distancing, a staggered work time, and wearing of personal protective equipment. Despite these challenging times, we continue to advance our programs with the ultimate goal of benefiting

patients. Before I review the progress we made in the last quarter, I would like to reflect on the headway our team has made in bringing 3 first-in-class drugs from concept to clinic in the last 18 months. I am incredibly proud and privileged to

lead such a passionate team. Even during these unprecedented times, what has not changed is our adherence to our core operating principles, as outlined on Slide 3. I strongly believe that the most important way we can deliver value to our

shareholders and our stakeholders is to advance toward important goals we laid out earlier this year because our company and our science must continue to evolve. As we work to become a key player in the gene and cell therapy market by realizing our

mission of improving patient care through our innovative product portfolio, I'm pleased to report that at this point, we remain largely on track with our previously disclosed clinical timeline. I will provide a more detailed update on our clinical

programs in just a moment. Our team also wants to underscore that we are on track to achieve the 2020 goals we laid out on our last call, while preserving financial resources, which should allow us to continue to operate well into 2021. We have made

considerable progress in streamlining the organization to focus on health. Key initiatives this quarter included: completing the sale of several of our non-health assets; improving operations at both Trans Ova Genetics and Exemplar, so they are net

contributors of capital this year barring significant adverse impact from the COVID-19 pandemic; and substantially reducing cash burn at MBP Titan, which I will discuss in greater detail later in the call. 1 THOMSON REUTERS | Contact Us 2 2020

logo are registered trademarks of Thomson Reuters and its affiliated companies.Exhibit 99.1 MAY 06, 2020 / 8:15PM GMT, Q1 2020 Precigen Inc Earnings Call CORPORATE PARTICIPANTS Helen Sabzevari Precigen, Inc. - President & CEO Steven Harasym

Precigen, Inc. - Head of Investor Relations Tom Samuelson Precigen, Inc. - Head of Financial Strategy CONFERENCE CALL PARTICIPANTS Jason Nicholas Butler JMP Securities LLC, Research Division - MD and Senior Research Analyst Swayampakula Ramakanth

H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst PRESENTATION Operator Good afternoon, and welcome to the Precigen First Quarter 2020 Business Update and Financial Results Conference Call. I

will now turn the call over to Steve Harasym, Head of Investor Relations. Please go ahead. Steven Harasym Precigen, Inc. - Head of Investor Relations Thank you, operator. I am pleased to be joined today by Dr. Helen Sabzevari, President and CEO of

Precigen; and Tom Samuelson, Head of Financial Strategy. Please turn to Slide 2 for our forward-looking statement. During today's call, we will make various forward-looking statements. Investors are cautioned that our forward-looking statements are

based on current expectations and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those indicated by our forward-looking statements. Please read the safe harbor statement contained in this

presentation as well as the risk factors contained in Precigen's most recent SEC filings, for a more complete discussion of these risks and uncertainties. I will now turn the call over to Dr. Sabzevari. Helen Sabzevari Precigen, Inc. - President

& CEO Thank you, Steve. I hope that this call finds all our listeners and their families safe and healthy. Since we last spoke in March, so much has changed. We are living through an historic moment that has caused profound change from all

perspectives: scientific, economic, sociologic and psychologic. Our nation and the world are making progress in working together to overcome the challenge of COVID-19. At Precigen, the health and safety of our employees is of the utmost importance.

Our corporate employees have transitioned seamlessly to working remotely, and essential personnel, including research scientists, are in the lab and practicing all appropriate safety measures, social distancing, a staggered work time, and wearing of

personal protective equipment. Despite these challenging times, we continue to advance our programs with the ultimate goal of benefiting patients. Before I review the progress we made in the last quarter, I would like to reflect on the headway our

team has made in bringing 3 first-in-class drugs from concept to clinic in the last 18 months. I am incredibly proud and privileged to lead such a passionate team. Even during these unprecedented times, what has not changed is our adherence to our

core operating principles, as outlined on Slide 3. I strongly believe that the most important way we can deliver value to our shareholders and our stakeholders is to advance toward important goals we laid out earlier this year because our company

and our science must continue to evolve. As we work to become a key player in the gene and cell therapy market by realizing our mission of improving patient care through our innovative product portfolio, I'm pleased to report that at this point, we

remain largely on track with our previously disclosed clinical timeline. I will provide a more detailed update on our clinical programs in just a moment. Our team also wants to underscore that we are on track to achieve the 2020 goals we laid out on

our last call, while preserving financial resources, which should allow us to continue to operate well into 2021. We have made considerable progress in streamlining the organization to focus on health. Key initiatives this quarter included:

completing the sale of several of our non-health assets; improving operations at both Trans Ova Genetics and Exemplar, so they are net contributors of capital this year barring significant adverse impact from the COVID-19 pandemic; and substantially

framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

MAY 06, 2020 / 8:15PM GMT, Q1 2020 Precigen Inc Earnings Call In the

first quarter of 2020, Precigen spending, which includes segment AEBITDA plus unallocated corporate costs was approximately $30 million versus $39 million in the first quarter of 2019. This decrease was primarily attributable to significantly lower

costs for corporate functions, which were streamlined to fit the narrower focus of the company. These numbers exclude the additional cost savings of $12 million, which resulted of the sale of certain of our non-core bioengineering assets, which

closed in the first quarter. Another top priority for us is to unify our health care businesses to become one Precigen, as you can see on Slide 4. We have made major strides here, allowing us to deploy resources, maximize collaboration and

streamline workflows more efficiently. Specifically, we have taken steps to integrate our health businesses to achieve synergies at both the corporate and company level. We have also streamlined our infrastructure, eliminated redundancies, reduced

corporate costs, and increased communication across our health businesses. In addition to Precigen, these include Precigen ActoBio, Precigen Exemplar and Precigen Triple-Gene. We have focused the efforts of our health subsidiaries on pipeline

programs that we believe have the most potential value. Externally, this closer integration is evidenced through our recently updated website, precigen.com, which consolidates information on each of these respective programs in one place. We hope

that you find it informative. On Slide 5, you will note our strategy for our non-healthcare assets. I'm pleased to report that we are making progress in our overall objective to reduce our capital allocation to both businesses. Consistent with our

goal to allocate resources in a manner that best creates value, it is our commitment to reduce non-health spending. We continue to implement additional efficiency measures at MBP Titan while exploring the options to partner or sell the business. The

ongoing COVID-19 pandemic and the current state of the energy sector are especially challenging for the prospect and operation of this business. We expect that progressing this non-health platform will require significant capital and efforts to

secure such capital have been hampered by world events. As a result, we have made the difficult but necessary decision to suspend operations in our MBP Titan facility and minimize the expense of the operation while continuing to maintain the

potential value of the platform for a brighter economic situation. Specifically, we have taken steps to significantly reduce our MBP Titan workforce and to cut operating costs, while at the same time, prioritizing the preservation of intellectual

property and technology. I also want to announce that by mutual agreement, David Witte, CEO of MBP Titan, is no longer with the company. I want to thank the entire MBP Titan team for their contribution in advancing our innovative Methane

Bioconversion Platform. We will continue to evaluate options for this technology. Another highlight this quarter was the upswing in financial performance at Trans Ova Genetics due to the combined impact of expanding the commercial dairy business and

achieving operational efficiencies. Turning now to update our health clinical programs on Slide 6, I am pleased to reaffirm that we remain on track to meet our previously announced goals for read-outs and other milestones in 2020. Turning to Slide

7. On April 20th, we announced that the FDA has cleared the Investigational New Drug application to initiate a Phase I/II trial for PRGN-2009, a first-in-class, off-the-shelf investigational immunotherapy, utilizing the AdenoVerse platform designed

to activate the immune system to recognize and target HPV-positive solid tumors. HPV-positive cancers represent a significant health burden in indications such as head and neck, cervical, vaginal and anal cancer. Globally, high-risk HPV infections

cause nearly 5% of all cancers. PRGN-2009 leverages Precigen UltraVector and AdenoVerse platforms, to optimize HPV antigen design in combination with its gorilla adenovector with a large payload capacity and the ability for repeat administration due

to very low to nonexistent seroprevalence in the human population. Preclinical testing of PRGN-2009 has demonstrated robust HPV antigen-specific immune response and potent anti-tumor activity as a monotherapy and in combination in humanized mouse

models of head and neck cancers. Please now turn to Slide 8. The Phase I portion of the study will follow 3+3 dose escalation to evaluate the safety of PRGN-2009 administrated as a monotherapy and to determine the recommended Phase II dose followed

is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.MAY 06, 2020 / 8:15PM GMT, Q1 2020 Precigen Inc Earnings

Call In the first quarter of 2020, Precigen spending, which includes segment AEBITDA plus unallocated corporate costs was approximately $30 million versus $39 million in the first quarter of 2019. This decrease was primarily attributable to

significantly lower costs for corporate functions, which were streamlined to fit the narrower focus of the company. These numbers exclude the additional cost savings of $12 million, which resulted of the sale of certain of our non-core

bioengineering assets, which closed in the first quarter. Another top priority for us is to unify our health care businesses to become one Precigen, as you can see on Slide 4. We have made major strides here, allowing us to deploy resources,

maximize collaboration and streamline workflows more efficiently. Specifically, we have taken steps to integrate our health businesses to achieve synergies at both the corporate and company level. We have also streamlined our infrastructure,

eliminated redundancies, reduced corporate costs, and increased communication across our health businesses. In addition to Precigen, these include Precigen ActoBio, Precigen Exemplar and Precigen Triple-Gene. We have focused the efforts of our

health subsidiaries on pipeline programs that we believe have the most potential value. Externally, this closer integration is evidenced through our recently updated website, precigen.com, which consolidates information on each of these respective

programs in one place. We hope that you find it informative. On Slide 5, you will note our strategy for our non-healthcare assets. I'm pleased to report that we are making progress in our overall objective to reduce our capital allocation to both

businesses. Consistent with our goal to allocate resources in a manner that best creates value, it is our commitment to reduce non-health spending. We continue to implement additional efficiency measures at MBP Titan while exploring the options to

partner or sell the business. The ongoing COVID-19 pandemic and the current state of the energy sector are especially challenging for the prospect and operation of this business. We expect that progressing this non-health platform will require

significant capital and efforts to secure such capital have been hampered by world events. As a result, we have made the difficult but necessary decision to suspend operations in our MBP Titan facility and minimize the expense of the operation while

continuing to maintain the potential value of the platform for a brighter economic situation. Specifically, we have taken steps to significantly reduce our MBP Titan workforce and to cut operating costs, while at the same time, prioritizing the

preservation of intellectual property and technology. I also want to announce that by mutual agreement, David Witte, CEO of MBP Titan, is no longer with the company. I want to thank the entire MBP Titan team for their contribution in advancing our

innovative Methane Bioconversion Platform. We will continue to evaluate options for this technology. Another highlight this quarter was the upswing in financial performance at Trans Ova Genetics due to the combined impact of expanding the commercial

dairy business and achieving operational efficiencies. Turning now to update our health clinical programs on Slide 6, I am pleased to reaffirm that we remain on track to meet our previously announced goals for read-outs and other milestones in 2020.

Turning to Slide 7. On April 20th, we announced that the FDA has cleared the Investigational New Drug application to initiate a Phase I/II trial for PRGN-2009, a first-in-class, off-the-shelf investigational immunotherapy, utilizing the AdenoVerse

platform designed to activate the immune system to recognize and target HPV-positive solid tumors. HPV-positive cancers represent a significant health burden in indications such as head and neck, cervical, vaginal and anal cancer. Globally,

high-risk HPV infections cause nearly 5% of all cancers. PRGN-2009 leverages Precigen UltraVector and AdenoVerse platforms, to optimize HPV antigen design in combination with its gorilla adenovector with a large payload capacity and the ability for

repeat administration due to very low to nonexistent seroprevalence in the human population. Preclinical testing of PRGN-2009 has demonstrated robust HPV antigen-specific immune response and potent anti-tumor activity as a monotherapy and in

combination in humanized mouse models of head and neck cancers. Please now turn to Slide 8. The Phase I portion of the study will follow 3+3 dose escalation to evaluate the safety of PRGN-2009 administrated as a monotherapy and to determine the

including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

MAY 06, 2020 / 8:15PM GMT, Q1 2020 Precigen Inc Earnings Call

investigational bifunctional fusion protein M7824 in patients with recurrent or metastatic HPV-associated cancers. The Phase II portion of this study will evaluate PRGN-2009 as a monotherapy or in combination with M7824 in patients with newly

diagnosed stage II or III HPV-16 positive oropharyngeal cancer. PRGN-2009 is under development through a Cooperative Research and Development Agreement, or CRADA, within the laboratory of Dr. Jeffrey Schlom at the National Cancer Institute. This

CRADA has allowed Precigen to rapidly and cost effectively advance PRGN-2009 to the clinic. The Phase I/II clinical trial will be conducted at the NCI and will be led by Dr. Julius Strauss and Dr. James Gulley. Turning to Slide 9. We reaffirm that

we are on track for initial data readouts from IP arm of our Phase I clinical trial of PRGN-3005 in ovarian cancer during the second half of this year. I am happy to announce that we have completed dosing of the dose level 2 of the IP arm of this

trial. We are very encouraged by our ability to successfully manufacture UltraCAR-T, and to date, we continue to have 100% manufacturing success. Fred Hutchinson Cancer Center has placed a temporary pause on non-COVID-19 Phase I clinical trials due

to the medical center's prioritization of COVID-19 patients at the hospital. PRGN-3005 was part of this pause. It is important to note that it was neither related to safety issues nor any study related COVID-19 infections. Today, I'm pleased to

announce that we are amongst the first trials to have the pause lifted and are actively recruiting again. As seen on Slide 10, we believe this is in part due to the characteristics of our platform, decentralized manufacturing advantages and lack of

lymphodepletion treatment to patients prior to UltraCAR-T administration. Unlike conventional CAR-T, UltraCAR-T cells do not use lentivirus and does not require long ex vivo expansion in large manufacturing facility. Instead, UltraCAR-T uses

nonviral, rapid manufacturing at the hospital, allowing for the treatment of patients the day after gene transfer. We view this as an important competitive advantage in a post COVID-19 world. Now moving to Slide 11. The PRGN-3006 trial continues to

enroll and to date has not experienced any COVID-19 related interruption. The trial was initially structured to dose patients in the non-lymphodepletion arm followed by the lymphodepletion arm at the set dose level. The IND has been amended, and the

FDA has allowed us to concurrently dose patients in both arms. We are currently enrolling patients in both lymphodepletion and non-lymphodepletion arms and are excited to compare them. And to date, we continue to have 100% manufacturing success. We

remain on track for initial data readouts and look at the kinetics in the second half of 2020. I will now go back to reviewing the rest of our portfolio on Slide 12. I would like to move on to ActoBio AG013, which is partnered with Oragenics.

Oragenics recently announced that early top-line results of the Phase II clinical trial of AG013 to prevent oral mucositis in the head and neck of cancer patients receiving chemo-radiation did not demonstrate a statistical significance on the

primary endpoint of severe oral mucositis durations when compared to placebo. We look forward to hearing from the company as developments become available. Turning now to AG019, as noted in earlier investor updates, Precigen ActoBio remains on track

to announce interim data for the first cohort of Phase IB/IIA clinical study in the third quarter of 2020. AG019 is a first-in-class, disease-modifying, antigen-specific investigational immunotherapy for prevention, delay or reversal of type 1

diabetes, a disease with no approved disease-modifying treatment that is currently managed through lifestyle modification and diet combined with exogenous insulin. We have implemented a temporary pause to randomization for the last remaining study

cohort of the Phase IIA study, which is the combination of AG019 plus anti-CD3 antibody, teplizumab, in patients 12 to 17 years of age. This temporary pause is neither due to any study-related issue nor is based on any study-related COVID-19

infections. We decided to do this out of an abundance of caution given the immunosuppressive nature of teplizumab against the background of the evolving COVID-19 pandemic. Another exciting asset in our portfolio is INXN-4001, a novel gene therapy

for heart failure patients, which is being developed by our majority-owned Precigen Triple-Gene subsidiary. We expect to complete the Phase I trial and provide top line data by the end of 2020. 3 THOMSON REUTERS | Contact Us 4 2020 Thomson

registered trademarks of Thomson Reuters and its affiliated companies.MAY 06, 2020 / 8:15PM GMT, Q1 2020 Precigen Inc Earnings Call investigational bifunctional fusion protein M7824 in patients with recurrent or metastatic HPV-associated cancers.

The Phase II portion of this study will evaluate PRGN-2009 as a monotherapy or in combination with M7824 in patients with newly diagnosed stage II or III HPV-16 positive oropharyngeal cancer. PRGN-2009 is under development through a Cooperative

Research and Development Agreement, or CRADA, within the laboratory of Dr. Jeffrey Schlom at the National Cancer Institute. This CRADA has allowed Precigen to rapidly and cost effectively advance PRGN-2009 to the clinic. The Phase I/II clinical

trial will be conducted at the NCI and will be led by Dr. Julius Strauss and Dr. James Gulley. Turning to Slide 9. We reaffirm that we are on track for initial data readouts from IP arm of our Phase I clinical trial of PRGN-3005 in ovarian cancer